Aptar Pharma

Setting the Standard for Drug Delivery

Nasal Drug Delivery Devices and Pain Management Systems

Aptar Pharma

Worth an estimated >2bn in 2009, the nasally administered systemic drugs market has an increasing generics sector, is placing greater emphasis on patient compliance and convenience, and is benefitting from an increasingly ageing population.

In contrast, severe pressure on health care costs is negatively affecting the market.

The Nasal route is beneficial due to its rapid onset of action, it is non-invasive, has good bio-availability, and patients can self-medicate.

Download this free whitepaper to find out more about the current trends in nasal drug delivery, including potential applications of nasal administration, recent additions to the marketplace, drugs soon to be added to the market, challenges and future opportunities, and potential e-device solutions.

Available Downloads